Log in for full access to this activity, if you are registered.

Registration Options

Activity Dates: 06/12/2014 - 04/29/2017

This course is closed. Please look for other available products in CPNP University.

Target Audience

This course is designed for pharmacists, nurse practitioners or other healthcare professionals involved in the comprehensive medication management of psychiatric and/or neurological patients.

Session Summary

Clozapine is a second generation antipsychotic drug primarily used to treat the symptoms of schizophrenia in patients who have not responded to other antipsychotic treatments. It is the only medication proven effective, approved for, and recommended for treatment-resistant schizophrenia. Despite these recommendations and current guidelines, prescription of clozapine in the U.S. is infrequent and disproportionately low (<5%) relative to the estimated prevalence of treatment-resistant schizophrenia and lower than many other countries worldwide. More appropriate prescribing of clozapine could lead to improvements in outcomes, but continued lack of use may lead to a future of suboptimal prescribing. While many barriers exist, clozapine’s low use is related in part to its frequent monitoring and serious side effects including agranulocytosis, myocarditis, seizures, sedation, obesity, diabetes mellitus and other metabolic abnormalities. This talk will review clozapine’s recommended place in therapy, treatment monitoring, and known barriers to use. In addition, it will focus on novel strategies for improving clozapine utilization and how pharmacists can play a significant role in the optimal use of this medication.

Course Requirements

You will proceed through the following steps to satisfactorily complete this course:

  • Review the full content of the activity and reflect upon its teachings.
  • Complete the post-test at the end of the activity no later than the closing activity date. (login first)
  • Complete the evaluation at the end of the activity. (login first)
  • If necessary, complete the post-test retest no later than the closing activity date. (login first)
  • Receive a passing grade (70%).
  • Provide the necessary details in your profile to ensure correct reporting by CPNP to CPE Monitor. (login first)

This course is provided online at cpnp.org and consists of the speaker audio and slides. A PDF file of the slides is also provided and access is available to participants indefinitely although ACPE credit is available only through the course expiration date.

Participants in this course must complete an examination and achieve a score of 70% or greater. Successful completion of the course also requires the completion of a course evaluation. ACPE statements of credit can be retrieved by participants online at cpnp.org immediately upon successful completion of the course.

Faculty Information and Disclosures

Learning Objectives

  1. Describe benefit of clozapine in treatment resistant schizophrenia.
  2. Briefly outline and review clozapine treatment and monitoring guidelines.
  3. Summarize rationale for clozapine underutilization.
  4. Discuss cutting-edge clinical and research strategies for increasing appropriate use in schizophrenia.

Continuing Education Credit and Disclosures

Activity Dates: 06/12/2014 - 04/29/2017
ACPE Contact Hours: 1.0
ACPE Number: 0284-0000-14-019-H01-P (Knowledge)
Nursing Credit Reminder: Note that ACPE credit is accepted for certification renewal.

ACPEThe College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This course provides 1.0 contact hours (0.10 CEUs) of knowledge-based continuing education credit. The ACPE universal program number assigned to this course is 0284-0000-14-019-H01-P (1.0 contact hours).